Dr. Belldegrun has been a leader in developing novel cancer treatments and closely involved with the founding and advancement of several successful private and public biopharmaceutical companies. In 1996, he founded Agensys, Inc., a biotechnology company, and served as its founding Chairman and as a board member until 2007, when it was acquired by Astellas Pharma Inc. From 2003 to 2009, he was the founding Vice-Chairman of the Board of Directors and Chairman of the Scientific Advisory Board of Cougar Biotechnology, Inc., until it was acquired by Johnson & Johnson. Dr. Belldegrun is the Chairman of Arno Therapeutics, Inc., Two River Group, and UroGen Pharma, Ltd. (formerly TheraCoat, Ltd.) and currently serves as a board member of Cell Design Labs. He is also a member of the Parker Institute for Cancer Immunotherapy’s Strategic Advisory Group. In addition, at the University of California, Los Angeles (UCLA), Dr. Belldegrun is Professor of Urology, holds the Roy and Carol Doumani Chair in Urologic Oncology, and is Director of the UCLA Institute of Urologic Oncology at the David Geffen School of Medicine. Prior to joining UCLA, he was a research fellow in surgical oncology and immunotherapy at the National Cancer Institute/NIH, working under Dr. Steven A. Rosenberg. Dr. Belldegrun earned his M.D. at the Hebrew University Hadassah Medical School in Jerusalem. He undertook his postgraduate studies in Immunology at the Weizmann Institute of Science, and his residency in Urologic Surgery at the Brigham and Women’s Hospital and Harvard Medical School in Boston, MA. He has authored several books in oncology and more than 500 scientific and medical papers related to urological cancers, immunotherapy, gene therapy, and cancer vaccines. He is certified by the American Board of Urology, and is a Fellow of the American College of Surgeons and the American Association of Genitourinary Surgeons.